Healthcare Executive Faints During Weight Loss Drug Announcement
Gordon Findlay, Healthcare Executive of Novo Nordisk, fainted Thursday at the Oval Office during an event announcing weight loss drugs.
Incident Details
The announcement about GLP-1 weight loss medications was interrupted as Mr. Findlay lost consciousness. President Donald Trump and Dr. Mehmet Oz immediately focused their attention on him.
"During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted," said White House Press Secretary Karoline Leavitt. "The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly.”
Event Context
The announcement highlighted a new deal with Eli Lilly and Novo Nordisk to offer some obesity drugs to Americans at about $150 per one-month supply.
At the time of Findlay’s fainting, Eli Lilly CEO David Ricks was delivering his speech. The press was quickly escorted out of the room. Dr. Kennedy left to get medical assistance, according to White House Deputy Press Secretary Kush Desai.
The press conference resumed shortly after 1:29 p.m.
Summary
This unexpected medical incident paused a key announcement on affordable obesity treatments but was managed quickly, allowing the event to continue.
Would you prefer a more detailed summary or additional sections for the medical response?